• Group sales rise to 531.7 million by + 5.7% against previous year.
• EBITDA at CHF 160.5 million (+2.0%) with a margin of 30.2%.
• Operating income EBIT at CHF 127.2 million (-1.3%) with a margin of 23.9%.
• Total investments of CHF 142.6 million and creation of 141 new positions.
• Board of Directors proposes an increase of the dividend by CHF 0.05 to CHF 0.75 per share.
Outlook:
• Bachem expects sales growth in 2023 to be significantly higher than in the previous year.
• The EBITDA margin is expected to remain stable at around 30% in 2023 compared to the previous year.
• Bachem is pursuing an extensive investment program across all sites and product categories to expand capacities. The commissioning of the new large-scale peptide and oligonucleotide production plant in Bubendorf is planned for 2024. By the end of the decade, a further production site is to be built at the new site in Eiken, Switzerland (Canton of Aargau).
Featuring:
Thomas Meier, CEO
Daniel Grotzky, Head of Communications
---------------------------------------------------------------------------------------------------------------------------
About Bachem:
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Learn more about our products and services at bit.ly/3LykCeY
28 авг 2024
